CTKB

Cytek Biosciences Inc

Add to Watchlist

Advanced Chart

3.690

+0.36(10.811%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.710

Open

3.400

VWAP

3.58

Vol

1.65M

Mkt Cap

467.37M

Low

3.380

Amount

5.91M

EV/EBITDA(TTM)

Total Shares

131.27M

161.07M

EV/OCF(TTM)

7.56

P/S(TTM)

2.20

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

58.05M

+1%

0.030

-74.02%

52.18M

+1.31%

0.010

-82.08%

46.03M

-1.25%

-0.020

+163.16%

Estimates Revision

The market is revising Downward the revenue expectations for Cytek Biosciences, Inc. (CTKB) for FY2025, with the revenue forecasts being adjusted by -3% over the past three months. During the same period, the stock price has changed by -2.12%.

Revenue Estimates for FY2025

Revise Downward

-3%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-90%

In Past 3 Month

Stock Price

Go Down

-2.12%

In Past 3 Month

4 Analyst Rating

55.83% Upside

Wall Street analysts forecast CTKB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTKB is 5.75 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

2 Hold

0 Sell

Moderate Buy

55.83% Upside

Current: 3.690

Low

4.00

Averages

5.75

High

8.00

55.83% Upside

Current: 3.690

Low

4.00

Averages

5.75

High

8.00

Morgan Stanley

Equal Weight

downgrade

$9 -> $7

2025-05-28

Reason

Morgan Stanley

Price Target

$9 -> $7

2025-05-28

downgrade

Equal Weight

Reason

Stephens

Overweight

maintain

$6 -> $4

2025-05-16

Reason

Stephens

Price Target

$6 -> $4

2025-05-16

maintain

Overweight

Reason

TD Cowen

Buy

Hold

downgrade

$7 -> $4

2025-05-09

Reason

TD Cowen

Price Target

$7 -> $4

2025-05-09

downgrade

Buy

Hold

Reason

TD Cowen downgraded Cytek Biosciences to Hold from Buy with a price target of $4, down from $7. The company's Q1 missed as multiple headwinds persist and the fiscal 2025 guidance was lowered, the analyst tells investors in a research note. The firm says that while Cytek remains a dominant flow cytometry player, it would stay on the sidelines pending better clarity on a path back to sustained growth.

Stephens & Co.

Mason Carrico

Buy

Reiterates

2025-03-19

Reason

Stephens & Co.

Mason Carrico

Price Target

2025-03-19

Reiterates

Buy

Reason

Piper Sandler

David Westenberg

Buy

Maintains

$8.5 → $8

2025-03-04

Reason

Piper Sandler

David Westenberg

Price Target

$8.5 → $8

2025-03-04

Maintains

Buy

Reason

Piper Sandler lowered the firm's price target on Cytek Biosciences to $8 from $8.25 following quarterly results. The firm keeps an Overweight rating on the shares.

Piper Sandler

David Westenberg

Buy

Maintains

$8 → $8.5

2024-11-11

Reason

Piper Sandler

David Westenberg

Price Target

$8 → $8.5

2024-11-11

Maintains

Buy

Reason

Piper Sandler raised the firm's price target on Cytek Biosciences to $8.50 from $8 following quarterly results. The firm keeps an Overweight rating on the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cytek Biosciences Inc (CTKB.O) is 133.20, compared to its 5-year average forward P/E of 100.07. For a more detailed relative valuation and DCF analysis to assess Cytek Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

100.07

Current PE

133.20

Overvalued PE

173.98

Undervalued PE

26.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

49.90

Current EV/EBITDA

27.74

Overvalued EV/EBITDA

90.16

Undervalued EV/EBITDA

9.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.20

Current PS

2.12

Overvalued PS

12.44

Undervalued PS

1.96

Financials

Annual

Quarterly

FY2025Q1

YoY :

-7.59%

41.46M

Total Revenue

FY2025Q1

YoY :

+39.51%

-14.98M

Operating Profit

FY2025Q1

YoY :

+84.83%

-11.40M

Net Income after Tax

FY2025Q1

YoY :

+80.00%

-0.09

EPS - Diluted

FY2025Q1

YoY :

-129.27%

-976.00K

Free Cash Flow

FY2025Q1

YoY :

-5.22%

48.62

Gross Profit Margin - %

FY2025Q1

YoY :

+1122.22%

8.80

FCF Margin - %

FY2025Q1

YoY :

+100.00%

-27.50

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

97.3K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

97.3K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CTKB News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

16:41:09

Cytek Biosciences cuts FY25 revenue view to $196M-$210M from $204M-$212M

2025-05-08

16:39:46

Cytek Biosciences reports Q1 EPS (9c) vs. (5c) last year

2025-02-27 (ET)

2025-02-27

16:53:38

Cytek Biosciences sees FY25 revenue $204M-$212M, consensus $216.52M

News

5.0

06-03NASDAQ.COM

Insider Purchase: Chief Financial Officer of $CTKB Buys 35,000 Shares

5.0

05-29Newsfilter

Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

2.0

05-28Benzinga

DHT Holdings Posts Weak Sales, Joins Compass Diversified, Okta And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

People Also Watch

Orrstown Financial Services Inc

Abacus Global Management Inc

Foresight Autonomous Holdings Ltd

Castle Biosciences Inc

NGL Energy Partners LP

4.260

USD

-1.62%

FAQ

What is Cytek Biosciences Inc (CTKB) stock price today?

The current price of CTKB is 3.69 USD — it has increased 10.81 % in the last trading day.

CTKB

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CTKB News & Events

Events Timeline

News

People Also Watch

FAQ

What is Cytek Biosciences Inc (CTKB) stock price today?

What is Cytek Biosciences Inc (CTKB)'s business?

What is the price predicton of CTKB Stock?

What is Cytek Biosciences Inc (CTKB)'s revenue for the last quarter?

What is Cytek Biosciences Inc (CTKB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Cytek Biosciences Inc (CTKB)'s fundamentals?

How many employees does Cytek Biosciences Inc (CTKB). have?

What is Cytek Biosciences Inc (CTKB) market cap?